159585-13-4

Usage

Uses

Used in Pharmaceutical Research and Development:
Pyrimidine, 4-chloro-6-(3-methoxyphenyl)-2-(methylthio)is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and potential biological activity make it a valuable candidate for the development of new drugs targeting a range of therapeutic areas.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Pyrimidine, 4-chloro-6-(3-methoxyphenyl)-2-(methylthio)serves as a building block for the design and synthesis of novel bioactive molecules. Its structural features can be further modified to optimize the pharmacological properties of the resulting compounds, enhancing their efficacy, selectivity, and safety.
Used in Drug Discovery:
Pyrimidine, 4-chloro-6-(3-methoxyphenyl)-2-(methylthio)plays a significant role in drug discovery processes, where it is employed as a starting material or a template for the development of new chemical entities. Its potential biological activity and diverse chemical reactivity make it a promising scaffold for the identification of lead compounds and the optimization of drug candidates.
Used in Chemical Synthesis:
Beyond its applications in the pharmaceutical industry, Pyrimidine, 4-chloro-6-(3-methoxyphenyl)-2-(methylthio)is also used in various chemical synthesis processes. Its unique functional groups and heterocyclic nature allow for a wide range of chemical reactions, enabling the preparation of diverse organic compounds for various applications.

Upstream product

• 766-85-8 3-methoxy-1-iodobenzene 
• 148256-79-5 4-chloro-6-iodo-2-(methylthio)pyrimidine 
• 49844-90-8 4-Chloro-2-methylthiopyrimidine 
• 6299-25-8 4,6-Dichloro-2-(methylthio)pyrimidine 
• 10365-98-7 3-methoxyphenylboronic acid 

Downstream Products

• 885067-64-1 4-chloro-2-methanesulfonyl-6-(3-methoxy-phenyl)-pyrimidine 

Relevant academic research and scientific papers

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.

2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

Metalation of diazines X: First halogen migration during metalation of pyrimidines unusual halogen-lithium exchange with LTMP new synthesis of Leshmaniacides

An halogen migration of iodine during the metalation of pyrimidines has been highlighted and a mechanism is proposed. An unusual halogen-lithium exchange with LTMP has been observed. A new synthetic route to Leshmaniacides using metalation and cross coupl